As US economic growth slows, the best prospects for investors will be in pharmaceutical and consumer...
As US economic growth slows, the best prospects for investors will be in pharmaceutical and consumer staples, according to Simon Laing, manager of the Newton American fund. Laing says: "We are overweight pharmaceutical companies as they will not be impacted by a US slowdown. If consumers start feeling the pinch of higher interest rates at 5.25% it is unlikely they will stop spending on medicines. They will stop spending money in the retail sector instead." One example in Laing's portfolio is drug company Wyeth, which saw its profits increase by 9% to $5.2bn for the second half of 2006. He...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes